Examples of using Caprelsa in English and their translations into German
{-}
-
Colloquial
-
Official
-
Ecclesiastic
-
Medicine
-
Financial
-
Ecclesiastic
-
Political
-
Computer
-
Programming
-
Official/political
-
Political
What is Caprelsa?
What is the risk associated with Caprelsa?
How does Caprelsa work?
Other information about Caprelsa.
How is Caprelsa used?
Other medicines and Caprelsa.
What is Caprelsa used for?
Caprelsa works by slowing down the growth of new blood vessels in tumours cancers.
Regularly during Caprelsa treatment.
The drug was developed by AstraZeneca and marketed under the trade name Caprelsa.
How has Caprelsa been studied?
Your doctor will discuss with you the benefits and risks of taking Caprelsa during this time.
Why has Caprelsa been approved?
Patients must be given a patient alert card containing important safety information andmust be informed by their doctor about the risks of Caprelsa.
Caprelsa 100 mg is a white round film-coated tablet with“Z100” imprinted on one side.
The most commonly reported side effects with Caprelsa are diarrhoea, rash, nausea(feeling sick), hypertension(high blood pressure) and head ache.
Caprelsa was more effective than placebo at prolonging progression free survival.
If you may become pregnant you must use effective contraception when you are taking Caprelsa and for at least four months after the last dose of Caprelsa.
Caprelsa 300 mg is a white oval-shaped film-coated tablet with“Z300” imprinted on one side.
In addition to this leaflet you will be given the Patient Alert Card, which contains important safety information that you need to know before you are given Caprelsa and during treatment with Caprelsa.
Caprelsa must not be used in patients who are taking certain other medicines that can prolong the QTc interval.
If you take more Caprelsa than you have been prescribed, talk to a doctor or go to a hospital straight away.
Caprelsa is used to treat medullary thyroid cancer that cannot be removed by surgery or has spread to other parts of the body.
Patients treated with Caprelsa must be given the patient alert card and be informed about the risks of Caprelsa see also package leaflet.
Caprelsa is used to treat medullary thyroid cancer, a type of cancer affecting the thyroid gland that originates in the cells that produce the hormone calcitonin.
The company that markets Caprelsa will carry out a study in patients with medullary thyroid cancer to compare the effects of Caprelsa in patients with and without the RET mutation.
Caprelsa is indicated for the treatment of aggressive and symptomatic medullary thyroid cancer(MTC) in patients with unresectable locally advanced or metastatic disease.
The CHMP concluded that Caprelsa was shown to be effective in the treatment of medullary thyroid cancer although there were uncertainties about the size of the benefit in patients whose RET mutation status is negative or unknown.
Caprelsa was compared with placebo(a dummy treatment) in a main study involving 331 patients with thyroid cancer that could not be removed by surgery or had spread to other parts of the body.
The company that markets Caprelsa will ensure that doctors who are expected to prescribe Caprelsa receive educational material containing important safety information about Caprelsa, including measures to manage the risk of QTc prolongation and other potential side effects, and a patient alert card.